Quantcast
Last updated on April 24, 2014 at 21:24 EDT

Latest Protein-bound paclitaxel Stories

2009-05-27 08:19:49

Research from the Northwestern University Feinberg School of Medicine has found that a less toxic, solvent-free chemotherapy drug more effectively prevents the progression of metastatic breast cancer and has fewer side effects than a commonly used solvent-based drug.A national study led by William Gradishar, M.D., director of breast medical oncology at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, found that the drug Abraxane prolonged progression-free survival...

2009-04-20 13:08:00

Proprietary tissue proteomics platform and strategic vision for future growth in pre-clinical and clinical biomarker research spur new financing ROCKVILLE, Md., April 20 /PRNewswire/ -- Expression Pathology Inc., a leading developer of technology for tissue protein analysis, announced that it has received additional financing of $6.5 million. The financing was led exclusively by Abraxis BioScience, a fully integrated, global biotechnology company. The financing will be used to apply...

2008-10-16 09:00:10

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, and Specialised Therapeutics Australia Pty Ltd, today announced that approval has been received from the Therapeutic Goods Administration (TGA) in Australia to market ABRAXANE(R) (nanoparticle albumin-bound paclitaxel) 100 mg powder for injection (suspension) for the treatment of metastatic carcinoma of the breast after failure of anthracycline therapy. The Phase III clinical trial results on which this...

2008-10-14 09:00:45

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced that Edward C. Geehr, M.D., has joined the company as Executive Vice President of Operations. Dr. Geehr, 59, will report to Patrick Soon-Shiong, M.D., Chairman and Chief Executive Officer of Abraxis BioScience. In this newly created position, Dr. Geehr will be responsible for the commercial, manufacturing and marketing operations of Abraxis. "Edward Geehr's extensive operational...

2008-10-08 09:00:51

The National Comprehensive Cancer Network, Abraxis BioScience and AstraZeneca have entered into a collaboration to conduct multiple investigator-initiated studies of Abraxis BioScience's anticancer drug Abraxane for injectable suspension, which is based on the company's proprietary tumor targeting technology known as the nab platform. The National Comprehensive Cancer Network (NCCN) studies will evaluate Abraxane in the treatment of breast, non-small cell lung, head and neck, melanoma and...

2008-10-08 09:00:36

Cenomed BioSciences, LLC, a majority-owned subsidiary of Abraxis BioScience, Inc. (Nasdaq: ABII), and TorreyPines Therapeutics, Inc. (Nasdaq: TPTX) today announced that they have entered into an exclusive licensing agreement whereby Cenomed acquired from TorreyPines Therapeutics the worldwide development rights held by TorreyPines to three compounds: phenserine, Posiphen(TM) and bisnorcymcerine, for chemical defense and counterterrorism defense. Cenomed intends to develop these compounds for...

2008-10-07 09:00:14

The National Comprehensive Cancer Network (NCCN), Abraxis BioScience (NASDAQ:ABII), and AstraZeneca (NYSE:AZN) today announced that they have entered into a collaboration to conduct multiple investigator-initiated studies of Abraxis BioScience's anti-cancer drug ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin bound), which is based on the company's proprietary tumor targeting technology known as the nab(TM) platform. The NCCN...

2008-07-18 09:01:12

Biocon and Abraxis BioScience have launched Abraxane in India for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant chemotherapy. Abraxane is now available in India as a single-use 100mg vial (as a lyophilized powder, to be reconstituted for intravenous administration). In October 2007, Abraxane was approved by the Drug Controller General of India. The approval was based on the clinical trial data that was...

2008-07-18 09:00:20

Biocon Limited, India's pioneering biotechnology company, and Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, today announced the launch of ABRAXANE(R) (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in India for the treatment of breast cancer after failure of combination therapy for metastatic disease or relapse within six months of adjuvant chemotherapy. ABRAXANE is now available in India as a single-use 100 mg vial (as a...

2008-07-14 12:00:20

Abraxis BioScience has received approval from the China State Food and Drug Administration to market Abraxane paclitaxel for injection for the treatment of breast cancer after failure of standard chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. The Phase III clinical trials in the US and China on which this approval was based demonstrated that Abraxane doubled the response rate, significantly prolonged time to tumor progression, and in the US trial,...